论文部分内容阅读
目的：探讨结直癌转移与可溶性Ｆａｓ（ｓＦａｓ）间的相关性。方法：应用酶联免疫吸附试验（ＥＬＩＳＡ）对４０例对照组和１２例结直肠癌患者血清中ｓＦａｓ浓度进行了测定。结果：对照组、原位癌和结直肠癌转移者血清中ｓＦａｓ浓度分别为２．３９７±１．３７９ｎｇ／ｍｌ、３．１５９±１．９０４ｎｇ／ｍｌ和７．９１４±２．１０５ｎｇ／ｍｌ。原位癌血清中ｓＦａｓ浓度高于对照组（Ｐ＜０．０１），而低于转移性直肠癌组（Ｐ＜０．０５），同时后者又明显高于对照组（Ｐ＜０．０１）。结论：ｓＦａｓ与结直肠癌转移有关，可能成为诊断其转移指标之一。
Objective: To investigate the correlation between cancer metastasis and soluble Fas (sFas). METHODS: Serum sFas concentrations in 40 patients with colorectal cancer and 12 patients with colorectal cancer were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: The serum sFas concentrations in the control group, carcinoma in situ, and metastatic colorectal cancer were 2.397±1.379 ng/ml, 3.159±1.904 ng/ml, and 7.914±2.105 ng/ml, respectively. The serum level of sFas in carcinoma in situ was higher than that in the control group (P<0.01), but lower than that in the metastatic rectal carcinoma group (P<0.05), while the latter was significantly higher than that in the control group (P<0.01). ). Conclusion: sFas is associated with metastasis of colorectal cancer and may be one of the indicators for the diagnosis of metastasis.